71308-91-3

Basic information

• Product Name: 2-bromo-5,6,7,8-tetrahydroquinoline
• Synonyms: 2-bromo-5,6,7,8-tetrahydroquinoline;2-bromo-5,6,7,8-tetrahydroquinoline(SALTDATA: FREE)
• CAS NO: 71308-91-3
• Molecular Formula: C₉H₁₀BrN
• Molecular Weight: 212.089
• Mol File: 71308-91-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-bromo-5,6,7,8-tetrahydroquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-5,6,7,8-tetrahydroquinoline(71308-91-3)
• EPA Substance Registry System: 2-bromo-5,6,7,8-tetrahydroquinoline(71308-91-3)

Safety Data

• Hazardous Substances Data: 71308-91-3(Hazardous Substances Data)

Usage

General Description

2-bromo-5,6,7,8-tetrahydroquinoline is a chemical compound with the molecular formula C10H11BrN. It is a brominated derivative of tetrahydroquinoline, which is a bicyclic structure found in many natural products and pharmaceuticals. 2-bromo-5,6,7,8-tetrahydroquinoline is used as a building block in organic synthesis and drug discovery, and its bromine substituent provides opportunities for further functionalization. 2-bromo-5,6,7,8-tetrahydroquinoline has potential applications in medicinal chemistry, agrochemicals, and materials science, and its unique structure and reactivity make it a valuable tool for chemical research and development.

Upstream product

• 21172-88-3 2-chloro-5,6,7,8-tetrahydro-quinoline 
• 4594-78-9 cyclohexanone-2-propionitrile 
• 54802-19-6 5,6,7,8-tetrahydro-1H-quinolin-2-one 
• 54802-19-6 2-hydroxy-5,6,7,8-tetrahydroquinoline 

Downstream Products

• 1357359-51-3 2-(2-fluorophenyl)-5,6,7,8-tetrahydroquinoline 
• 1357359-55-7 2,6-diisopropyl-N-(2-(5,6,7,8-tetrahydroquinolin-2-yl)phenyl)aniline 
• 1357387-17-7 F₂BC₉H₁₀NC₆H₄NC₆H₃(CH(CH₃)2)2 

Relevant articles and documents

Pyrazolone-fused pyrimidine compound as well as preparation method and application thereof

The invention discloses a pyrazolone-fused pyrimidine compound as well as a preparation method and application thereof. The invention provides a pyrazolone-fused pyrimidine compound as shown in a formula I which is described in the specification. The pyrazolone-fused pyrimidine compound has better inhibitory activity on WEE1 kinase.

Heterocyclic compounds as inhibitors of factor VIIa

The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.